Crispr Therapeutics [CRSP] vs Vertex [VRTX] Detailed Stock Comparison

Crispr Therapeutics AG

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Crispr Therapeutics AG wins in 3 metrics, Vertex Pharmaceuticals Inc. wins in 15 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Crispr Therapeutics AG Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) -8.52 28.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio 2.77 5.92 Crispr Therapeutics AG
Debt-to-Equity Ratio 10.76 10.91 Crispr Therapeutics AG
PEG Ratio -0.04 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -6.49 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 0.00% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -17,912.50% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -30.18% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -15.76% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-370.93M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 54.81% 1.24% Crispr Therapeutics AG
Price-to-Sales Ratio (TTM) 1,518.81 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $3.56B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 1,014.80 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) $0 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-6.47 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 1.79 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 26.43% 1.78% Vertex Pharmaceuticals Inc.

Crispr Therapeutics AG vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

CRSP
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Crispr Therapeutics AG0.15%-2.67%-2.76%-10.27%-6.95%-3.11%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Crispr Therapeutics AG54.81%-13.57%-50.41%306.51%306.51%306.51%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Crispr Therapeutics AG vs Vertex Pharmaceuticals Inc.

MetricCRSPVRTX
Market Information
Market Cap i$5.30B$109.45B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i1,664,9331,057,061
90 Day Avg. Volume i2,131,1411,272,097
Last Close$52.10$428.34
52 Week Range$36.08 - $78.48$362.50 - $507.92
% from 52W High-33.61%-15.67%
All-Time High$220.20 (Jan 11, 2021)$519.88 (Nov 04, 2024)
% from All-Time High-76.34%-17.61%
Growth Metrics
Quarterly Revenue Growth-0.98%0.10%
Quarterly Earnings Growth-1.00%0.31%
Financial Health
Profit Margin (TTM) i0.00%0.33%
Operating Margin (TTM) i-179.13%0.40%
Return on Equity (TTM) i-0.30%0.23%
Debt to Equity (MRQ) i10.7610.91
Cash & Liquidity
Book Value per Share (MRQ)$20.04$73.49
Cash per Share (MRQ)$20.59$26.01
Operating Cash Flow (TTM) i$-345,014,016$3.63B
Levered Free Cash Flow (TTM) i$-205,623,744$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Crispr Therapeutics AG vs Vertex Pharmaceuticals Inc.

MetricCRSP (Apr 24, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-8.5228.40
Forward P/E i-13.2619.95
PEG Ratio i-0.040.88
Price to Sales (TTM) i1,518.819.22
Price to Book (MRQ) i2.775.92
Market Capitalization
Market Capitalization i$5.30B$109.45B
Enterprise Value i$3.56B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i1,014.808.83
Enterprise to EBITDA i-6.4921.78
Risk & Other Metrics
Beta i1.790.37
Book Value per Share (MRQ) i$20.04$73.49

Financial Statements Comparison: Crispr Therapeutics AG vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCRSP (2025)VRTX (2025)
Revenue/Sales i012.00B
Cost of Goods Sold i213.48M1.65B
COGS % of Revenue i-13.8%
Gross Profit i-213.48M10.35B
Gross Margin i-86.2%
Research & Development i381.06M4.04B
Operating Income (EBIT) i-664.57M4.55B
Operating Margin i-37.9%
EBITDA i-645.09M5.25B
EBITDA Margin i-43.7%
Pre-Tax Income i-577.97M4.64B
Pre-Tax Income % of Revenue i-38.7%
Income Tax i3.63M690.00M
Income Tax % of Revenue i-5.7%
Net Income (Profit) i-581.60M3.95B
Profit Margin i-32.9%

Balance Sheet & Liquidity Metrics

MetricCRSP (2025)VRTX (2025)
Cash & Equivalents i347.56M5.08B
Total Current Assets i1.99B11.20B
Total Current Assets % of Revenue i-93.3%
Total Current Liabilities i149.12M3.86B
Total Current Liabilities % of Revenue i-32.2%
Long-Term Debt i188.17M1.95B
Long-Term Debt % of Revenue i-16.3%
Total Shareholders Equity i1.92B18.67B
Retained Earnings i-1.95B13.56B
Retained Earnings % of Revenue i-113.0%
Property, Plant & Equipment i175.30M1.56B

Cash Flow Statement Comparison

MetricCRSP (2025)VRTX (2025)
Operating Cash Flow i-393.25M3.77B
Operating Cash Flow % of Revenue i-31.4%
Capital Expenditures i-914,000-437.60M
Free Cash Flow i-370.93M3.19B
FCF Margin i-26.6%
Debt Repayment iN/A-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricCRSPVRTX
Shares Short i22.62M4.02M
Short Ratio i10.012.80
Short % of Float i26.43%1.78%
Shares Outstanding i95.89M253.99M
Float Shares i95.55M253.24M
% Held by Insiders i4.88%0.21%
% Held by Institutions i73.33%97.60%
% Held by Public i21.79%2.19%

Dividend Analysis & Yield Comparison: Crispr Therapeutics AG vs Vertex Pharmaceuticals Inc.

MetricCRSPVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A